On this episode, we’re featuring discussions about data in colorectal cancer that were presented at the 2022 ASCO Annual Meeting. Dr. Michael Overman, of The University of Texas MD Anderson Cancer Center, speaks with two presenters about guiding therapy with circulating tumor DNA and refining treatment strategies for RAS wild-type metastatic disease.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Dr. Courtney DiNardo, of The University of Texas MD Anderson Cancer Center, sat down with two colleagues at the 2022 ASCO Annual Meeting to discuss data presented in leukemia. On this episode of the podcast, we’re featuring Dr. DiNardo’s conversations.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re featuring discussions on lung cancer that took place at the 2022 ASCO Annual Meeting. They were led by Dr. Gilberto de Lima Lopes, Jr, of the Sylvester Comprehensive Cancer Center at the University of Miami. The first focuses on data from a study of a novel bispecific antibody in patients with non–small cell lung cancer that exhibits the MET exon 14 skipping mutation. The second focuses on an analysis of patients with lung cancer treated with chemoimmunotherapy regimens.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

At the 2022 ASCO Annual Meeting, Dr. Ann Partridge, of Dana-Farber Cancer Institute, discussed trends in breast cancer with several colleagues. On this episode, we’re featuring two of those conversations: one on antibody-drug conjugates, and another on endocrine therapy plus ribociclib for progressive breast cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, we’re featuring two conversations focusing on gynecologic oncology, both led by Dr. Ursula Matulonis, of Dana-Farber Cancer Institute. Dr. Matulonis, along with two colleagues, reviews data presented at the 2022 ASCO Annual Meeting in ovarian, primary peritoneal, and fallopian tube cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, we’re featuring two conversations focusing on gynecologic oncology, both led by Dr. Ursula Matulonis, of Dana-Farber Cancer Institute. Dr. Matulonis, along with two colleagues, reviews data presented at the 2022 ASCO Annual Meeting in ovarian, primary peritoneal, and fallopian tube cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, we’re featuring two conversations from leaders in the field of genitourinary oncology. These discussions go over long-term findings in prostate cancer and urothelial carcinoma, and were both presented at the 2022 ASCO Annual Meeting.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, we’ll hear about results from the phase III DETERMINATION trial in multiple myeloma, and a study that sought to determine when radiotherapy may be avoided after breast-conserving surgery.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, we continue to highlight research presented at the 2022 ASCO Annual Meeting. We’ll first hear a discussion between two researchers on Plenary Abstract LBA1, which may establish a standard first-line combination regimen for patients with RAS wild-type and left-sided metastatic colorectal cancer. Then, we’ll hear about a study that highlighted the need to increase participation in clinical trials amongst Black women with metastatic breast cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, we’ll hear about results from the phase III DETERMINATION trial in multiple myeloma, and a study that sought to determine when radiotherapy may be avoided after breast-conserving surgery.

To listen to more podcasts from ASCO, visit asco.org/podcasts.